APO Research
Talk to an analyst

APO RESEARCH · REPORT

Group A and C Meningococcal Polysaccharide Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Group A and C Meningococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026

27 December 2025193 pages

Choose your research edition.

Industry ResearchGroup A and C Meningococcal Polysaccharide Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Group A and C Meningococcal Polysaccharide Vaccine Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Group A and C Meningococcal Polysaccharide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Group A and C Meningococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Group A and C Meningococcal Polysaccharide Vaccine Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Group A and C Meningococcal Polysaccharide Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Group A and C Meningococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Group A and C Meningococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Group A and C Meningococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Group A and C Meningococcal Polysaccharide Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Group A and C Meningococcal Polysaccharide Vaccine market include Pfizer, Sanofi Pasteur, AIM Bio, Chengda Biotechnology, GlaxoSmithKline, Cansino Biologics, Sinovac, Lanzhou Institute of Biological Products and Royal (Wuxi) Bio-Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Group A and C Meningococcal Polysaccharide Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Group A and C Meningococcal Polysaccharide Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Group A and C Meningococcal Polysaccharide Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Group A and C Meningococcal Polysaccharide Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Group A and C Meningococcal Polysaccharide Vaccine Segment by Company

Pfizer

Sanofi Pasteur

AIM Bio

Chengda Biotechnology

GlaxoSmithKline

Cansino Biologics

Sinovac

Lanzhou Institute of Biological Products

Royal (Wuxi) Bio-Pharmaceutical

Merck & Co.

Toyouvax

Walvax

Zhifei Biological

Group A and C Meningococcal Polysaccharide Vaccine Segment by Type

Polysaccharide-protein Conjugate Vaccine

Polysaccharide Vaccine

Group A and C Meningococcal Polysaccharide Vaccine Segment by Application

Hospital

Centers for Disease Control and Prevention

Others

Group A and C Meningococcal Polysaccharide Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Group A and C Meningococcal Polysaccharide Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Group A and C Meningococcal Polysaccharide Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Group A and C Meningococcal Polysaccharide Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Group A and C Meningococcal Polysaccharide Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Group A and C Meningococcal Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Group A and C Meningococcal Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Group A and C Meningococcal Polysaccharide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Group A and C Meningococcal Polysaccharide Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Group A and C Meningococcal Polysaccharide Vaccine industry.

Chapter 3: Detailed analysis of Group A and C Meningococcal Polysaccharide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Group A and C Meningococcal Polysaccharide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Group A and C Meningococcal Polysaccharide Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Group A and C Meningococcal Polysaccharide Vaccine Industry Trends Table 2. Group A and C Meningococcal Polysaccharide Vaccine Industry Drivers Table 3. Group A and C Meningococcal Polysaccharide Vaccine Industry Opportunities and Challenges Table 4. Group A and C Meningococcal Polysaccharide Vaccine Industry Restraints Table 5. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Company (2021-2026) Table 7. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume by Company (Units) & (2021-2026) Table 8. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Group A and C Meningococcal Polysaccharide Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Group A and C Meningococcal Polysaccharide Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Group A and C Meningococcal Polysaccharide Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Group A and C Meningococcal Polysaccharide Vaccine Company, Product Type & Application Table 13. Global Group A and C Meningococcal Polysaccharide Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Group A and C Meningococcal Polysaccharide Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Polysaccharide-protein Conjugate Vaccine Table 18. Significant Companies of Polysaccharide Vaccine Table 19. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 20. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume by Type (2021-2026) & (Units) Table 21. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume by Type (2027-2032) & (Units) Table 22. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Centers for Disease Control and Prevention Table 31. Significant Companies of Others Table 32. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 33. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume by Application (2021-2026) & (Units) Table 34. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume by Application (2027-2032) & (Units) Table 35. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume Share by Application (2021-2026) Table 36. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume Share by Application (2027-2032) Table 37. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application (2021-2026) Table 41. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application (2027-2032) Table 42. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 43. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2021-2026) & (Units) Table 44. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2027-2032) & (Units) Table 46. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2027-2032) Table 47. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Region (2021-2026) Table 50. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Region (2027-2032) Table 52. Global Group A and C Meningococcal Polysaccharide Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Group A and C Meningococcal Polysaccharide Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 55. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (Units) Table 57. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2026) Table 58. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (Units) Table 59. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2027-2032) Table 60. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Market Share by Country (2021-2026) Table 62. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Market Share by Country (2027-2032) Table 64. Pfizer Company Information Table 65. Pfizer Business Overview Table 66. Pfizer Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Pfizer Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 68. Pfizer Recent Development Table 69. Sanofi Pasteur Company Information Table 70. Sanofi Pasteur Business Overview Table 71. Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 73. Sanofi Pasteur Recent Development Table 74. AIM Bio Company Information Table 75. AIM Bio Business Overview Table 76. AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 78. AIM Bio Recent Development Table 79. Chengda Biotechnology Company Information Table 80. Chengda Biotechnology Business Overview Table 81. Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 83. Chengda Biotechnology Recent Development Table 84. GlaxoSmithKline Company Information Table 85. GlaxoSmithKline Business Overview Table 86. GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 88. GlaxoSmithKline Recent Development Table 89. Cansino Biologics Company Information Table 90. Cansino Biologics Business Overview Table 91. Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 93. Cansino Biologics Recent Development Table 94. Sinovac Company Information Table 95. Sinovac Business Overview Table 96. Sinovac Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Sinovac Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 98. Sinovac Recent Development Table 99. Lanzhou Institute of Biological Products Company Information Table 100. Lanzhou Institute of Biological Products Business Overview Table 101. Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 103. Lanzhou Institute of Biological Products Recent Development Table 104. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 105. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 106. Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 108. Royal (Wuxi) Bio-Pharmaceutical Recent Development Table 109. Merck & Co. Company Information Table 110. Merck & Co. Business Overview Table 111. Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 113. Merck & Co. Recent Development Table 114. Toyouvax Company Information Table 115. Toyouvax Business Overview Table 116. Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 118. Toyouvax Recent Development Table 119. Walvax Company Information Table 120. Walvax Business Overview Table 121. Walvax Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Walvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 123. Walvax Recent Development Table 124. Zhifei Biological Company Information Table 125. Zhifei Biological Business Overview Table 126. Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 128. Zhifei Biological Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Group A and C Meningococcal Polysaccharide Vaccine Distributors List Table 132. Group A and C Meningococcal Polysaccharide Vaccine Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Group A and C Meningococcal Polysaccharide Vaccine Product Image Figure 2. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Group A and C Meningococcal Polysaccharide Vaccine Sales (2021-2032) & (Units) Figure 5. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Group A and C Meningococcal Polysaccharide Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Polysaccharide-protein Conjugate Vaccine Image Figure 10. Polysaccharide Vaccine Image Figure 11. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 12. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Centers for Disease Control and Prevention Image Figure 19. Others Image Figure 20. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 21. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume Share by Application (2021-2032) Figure 23. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application (2021-2032) Figure 26. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 27. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Group A and C Meningococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Group A and C Meningococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Group A and C Meningococcal Polysaccharide Vaccine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Group A and C Meningococcal Polysaccharide Vaccine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Polysaccharide-protein Conjugate Vaccine
  • Polysaccharide Vaccine
Applications
  • Hospital
  • Centers for Disease Control and Prevention
  • Others
Companies covered
  • Pfizer
  • Sanofi Pasteur
  • AIM Bio
  • Chengda Biotechnology
  • GlaxoSmithKline
  • Cansino Biologics
  • Sinovac
  • Lanzhou Institute of Biological Products
  • Royal (Wuxi) Bio-Pharmaceutical
  • Merck & Co.
  • Toyouvax
  • Walvax
  • Zhifei Biological

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Group A and C Meningococcal Polysaccharide Vaccine Market Dynamics
  1. 2.1 Group A and C Meningococcal Polysaccharide Vaccine Industry Trends
  2. 2.2 Group A and C Meningococcal Polysaccharide Vaccine Industry Drivers
  3. 2.3 Group A and C Meningococcal Polysaccharide Vaccine Industry Opportunities and Challenges
  4. 2.4 Group A and C Meningococcal Polysaccharide Vaccine Industry Restraints
3 Group A and C Meningococcal Polysaccharide Vaccine Market by Company
  1. 3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Group A and C Meningococcal Polysaccharide Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Group A and C Meningococcal Polysaccharide Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Group A and C Meningococcal Polysaccharide Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Group A and C Meningococcal Polysaccharide Vaccine Company Product Type and Application
  8. 3.8 Global Group A and C Meningococcal Polysaccharide Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Group A and C Meningococcal Polysaccharide Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Group A and C Meningococcal Polysaccharide Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Group A and C Meningococcal Polysaccharide Vaccine Market by Type
  1. 4.1 Group A and C Meningococcal Polysaccharide Vaccine Type Introduction
  2. 4.1.1 Polysaccharide-protein Conjugate Vaccine
  3. 4.1.2 Polysaccharide Vaccine
  4. 4.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume by Type
  5. 4.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Type
  9. 4.3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type (2021-2032)
5 Group A and C Meningococcal Polysaccharide Vaccine Market by Application
  1. 5.1 Group A and C Meningococcal Polysaccharide Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Centers for Disease Control and Prevention
  4. 5.1.3 Others
  5. 5.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume by Application
  6. 5.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Application
  10. 5.3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application (2021-2032)
6 Group A and C Meningococcal Polysaccharide Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Group A and C Meningococcal Polysaccharide Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Group A and C Meningococcal Polysaccharide Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Group A and C Meningococcal Polysaccharide Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
7 Group A and C Meningococcal Polysaccharide Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Group A and C Meningococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Group A and C Meningococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 Sanofi Pasteur
  8. 8.2.1 Sanofi Pasteur Company Information
  9. 8.2.2 Sanofi Pasteur Business Overview
  10. 8.2.3 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  12. 8.2.5 Sanofi Pasteur Recent Developments
  13. 8.3 AIM Bio
  14. 8.3.1 AIM Bio Company Information
  15. 8.3.2 AIM Bio Business Overview
  16. 8.3.3 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  18. 8.3.5 AIM Bio Recent Developments
  19. 8.4 Chengda Biotechnology
  20. 8.4.1 Chengda Biotechnology Company Information
  21. 8.4.2 Chengda Biotechnology Business Overview
  22. 8.4.3 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  24. 8.4.5 Chengda Biotechnology Recent Developments
  25. 8.5 GlaxoSmithKline
  26. 8.5.1 GlaxoSmithKline Company Information
  27. 8.5.2 GlaxoSmithKline Business Overview
  28. 8.5.3 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  30. 8.5.5 GlaxoSmithKline Recent Developments
  31. 8.6 Cansino Biologics
  32. 8.6.1 Cansino Biologics Company Information
  33. 8.6.2 Cansino Biologics Business Overview
  34. 8.6.3 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  36. 8.6.5 Cansino Biologics Recent Developments
  37. 8.7 Sinovac
  38. 8.7.1 Sinovac Company Information
  39. 8.7.2 Sinovac Business Overview
  40. 8.7.3 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  42. 8.7.5 Sinovac Recent Developments
  43. 8.8 Lanzhou Institute of Biological Products
  44. 8.8.1 Lanzhou Institute of Biological Products Company Information
  45. 8.8.2 Lanzhou Institute of Biological Products Business Overview
  46. 8.8.3 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  48. 8.8.5 Lanzhou Institute of Biological Products Recent Developments
  49. 8.9 Royal (Wuxi) Bio-Pharmaceutical
  50. 8.9.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  51. 8.9.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
  52. 8.9.3 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  54. 8.9.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
  55. 8.10 Merck & Co.
  56. 8.10.1 Merck & Co. Company Information
  57. 8.10.2 Merck & Co. Business Overview
  58. 8.10.3 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  60. 8.10.5 Merck & Co. Recent Developments
  61. 8.11 Toyouvax
  62. 8.11.1 Toyouvax Company Information
  63. 8.11.2 Toyouvax Business Overview
  64. 8.11.3 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  66. 8.11.5 Toyouvax Recent Developments
  67. 8.12 Walvax
  68. 8.12.1 Walvax Company Information
  69. 8.12.2 Walvax Business Overview
  70. 8.12.3 Walvax Group A and C Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Walvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  72. 8.12.5 Walvax Recent Developments
  73. 8.13 Zhifei Biological
  74. 8.13.1 Zhifei Biological Company Information
  75. 8.13.2 Zhifei Biological Business Overview
  76. 8.13.3 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  78. 8.13.5 Zhifei Biological Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Group A and C Meningococcal Polysaccharide Vaccine Value Chain Analysis
  2. 9.1.1 Group A and C Meningococcal Polysaccharide Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Group A and C Meningococcal Polysaccharide Vaccine Sales Mode & Process
  6. 9.2 Group A and C Meningococcal Polysaccharide Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Group A and C Meningococcal Polysaccharide Vaccine Distributors
  9. 9.2.3 Group A and C Meningococcal Polysaccharide Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst